EE356 Budget Impact Analysis on Blinatumomab for the Treatment of Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R BCP-ALL)

Abstract

Authors

J Zhao G Jin L Yang

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×